Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 14, 2026; 32(26): 117924
Published online Jul 14, 2026. doi: 10.3748/wjg.117924
Published online Jul 14, 2026. doi: 10.3748/wjg.117924
Table 4 Multivariable logistic regression analysis of clinical risk assessment factors
| Characteristic | P value | OR | 95%CI |
| BMI before treatment (> 24 kg/m2) | 0.06 | 6.72 | 1.04-66.3 |
| CRM (threatened) | 0.11 | 5.97 | 0.732-68.1 |
| Tumor size (> 4 cm) | 0.036 | 6.51 | 1.23-45.2 |
| Before treatment CEA (> 5 ng/mL) | 0.035 | 0.12 | 0.01-0.73 |
- Citation: Qiang WD, Wei Q, Yang B, Chen WJ, Lin CQ, Li YX. Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial. World J Gastroenterol 2026; 32(26): 117924
- URL: https://www.wjgnet.com/1007-9327/full/v32/i26/117924.htm
- DOI: https://dx.doi.org/10.3748/wjg.117924